Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Loic, Verlingue"'
Autor:
Loic Verlingue, Antoine Italiano, Hans Prenen, Eva Maria Guerra Alia, Diego Tosi, Ruth Perets, Iwona Lugowska, Vladimir Moiseyenko, Mahmut Gumus, Cagatay Arslan, Colin R. Lindsay, Sanjeev Deva, Álvaro Taus, Ana Oaknin, Sylvie Rottey, Irfan Cicin, Sema Sezgin Goksu, Alexey Smolin, Susana Roselló-Keränen, Christin Habigt, Daniel Marbach, Christophe Boetsch, David Dejardin, Nassim Sleiman, Stefan Evers, Muriel Richard, Caroline Ardeshir, Jehad Charo, Anton Kraxner, Volker Teichgräber, Nino Keshelava, Rafal Dziadziuszko
Publikováno v:
EBioMedicine, Vol 109, Iss , Pp 105374- (2024)
Summary: Background: Simlukafusp alfa (FAP-IL2v) is an immune cytokine engineered to selectively promote immune responses in the tumour microenvironment. We evaluated the antitumour activity and safety of FAP-IL2v plus atezolizumab in recurrent and/o
Externí odkaz:
https://doaj.org/article/2eb15235333d4a14935f9abccb626cd2
Autor:
Antonin Levy, Daphné Morel, Matthieu Texier, Roger Sun, Jerome Durand-Labrunie, Maria E Rodriguez-Ruiz, Severine Racadot, Stéphane Supiot, Nicolas Magné, Stacy Cyrille, Guillaume Louvel, Christophe Massard, Loic Verlingue, Fanny Bouquet, Alberto Bustillos, Lisa Bouarroudj, Clément Quevrin, Céline Clémenson, Michele Mondini, Lydia Meziani, Lambros Tselikas, Rastilav Bahleda, Antoine Hollebecque, Eric Deutsch
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-13 (2024)
Abstract Background Immuno-radiotherapy may improve outcomes for patients with advanced solid tumors, although optimized combination modalities remain unclear. Here, we report the colorectal (CRC) cohort analysis from the SABR-PDL1 trial that evaluat
Externí odkaz:
https://doaj.org/article/e2332711ee644fd79fb6e8ed2a5b6190
Autor:
Loic Verlingue, Marine Desevre, Marie Polito, Gwenaelle Garin, Christine Rodriguez, Wang Qing, Olivier Tredan, David Perol, Isabelle Ray-Coquard, Sylvie Chabaud, Jean Yves Blay
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: In this manuscript we describe the academic French multicentric molecular analysis platforms including PROFILER, promoted by Centre Léon Berard, and the multicentric personalized medicine trials MOST, MOST Plus and MEGAMOST.
Externí odkaz:
https://doaj.org/article/5a5aac5322d3492c902a4906dd1fdeb6
Autor:
Kjetil Taskén, Soemeya F. Haj Mohammad, Gro Live Fagereng, Ragnhild Sørum Falk, Åslaug Helland, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Katarina Steen Carlsson, Bettina Ryll, Katriina Jalkanen, Anders Edsjö, Hege G. Russnes, Ulrik Lassen, Ebba Hallersjö Hult, Iwona Lugowska, Jean-Yves Blay, Loic Verlingue, Edvard Abel, Maeve A. Lowery, Matthew G. Krebs, Kristoffer Staal Rohrberg, Kristiina Ojamaa, Julio Oliveira, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation o
Externí odkaz:
https://doaj.org/article/a341b8825c7a4512be06dc2a4bf54da1
Autor:
Patricia, Martin-Romano, Leo, Colmet-Daage, Daphne, Morel, Capucine, Baldini, Loic, Verlingue, Rastilav, Bahleda, Anas, Gazzah, Stephan, Champiat, Andree, Varga, Jean Marie, Michot, Maud, Ngo-Camus, Claudio, Nicotra, Aurelien, Marabelle, Jean Charles, Soria, Etienne, Rouleau, Ludovic, Lacroix, Antoine, Hollebecque, Christophe, Massard, Sophie, Postel-Vinay
Publikováno v:
European Journal of Cancer. 173:133-145
Although the role of epigenetic alterations in oncogenesis has been well studied, their prevalence in metastatic solid tumours is still poorly described. We therefore aimed at: (i) describing the presence of epigenetic gene alterations (EGA) - define
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8024c5c9089cc5c5e59f2323e9efe197
https://doi.org/10.1016/j.ejca.2022.06.014
https://doi.org/10.1016/j.ejca.2022.06.014
Data from Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
Autor:
Sergey I. Nikolaev, Daniel Gautheret, Paul-Henry Cournède, Fabrice André, Luc Friboulet, Benjamin Besse, Yohann Loriot, Antoine Lainé, Laura Mezquita, Gérôme Jules-Clément, Antoine Hollebecque, Stefan Michiels, Leonardo Panunzi, Ismael Padioleau, Véronique Scott, Loic Verlingue, Guillaume Grisay, Marc Deloger, Luigi Cerbone, Konstantin Gunbin, Andrey A. Yurchenko, Julien Viot, Yoann Pradat
Metastatic relapse after treatment is the leading cause of cancer mortality, and known resistance mechanisms are missing for most treatments administered to patients. To bridge this gap, we analyze a pan-cancer cohort (META-PRISM) of 1,031 refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ebc36ddae7728a3e2b1010d142f8822
https://doi.org/10.1158/2159-8290.c.6615885
https://doi.org/10.1158/2159-8290.c.6615885
Autor:
Sergey I. Nikolaev, Daniel Gautheret, Paul-Henry Cournède, Fabrice André, Luc Friboulet, Benjamin Besse, Yohann Loriot, Antoine Lainé, Laura Mezquita, Gérôme Jules-Clément, Antoine Hollebecque, Stefan Michiels, Leonardo Panunzi, Ismael Padioleau, Véronique Scott, Loic Verlingue, Guillaume Grisay, Marc Deloger, Luigi Cerbone, Konstantin Gunbin, Andrey A. Yurchenko, Julien Viot, Yoann Pradat
These figures provide complementary information for the figures presented in the main text and illustrations of the methods section.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c1e3a740d395bcf770a80c481726b1e
https://doi.org/10.1158/2159-8290.22758879.v1
https://doi.org/10.1158/2159-8290.22758879.v1
Autor:
Sergey I. Nikolaev, Daniel Gautheret, Paul-Henry Cournède, Fabrice André, Luc Friboulet, Benjamin Besse, Yohann Loriot, Antoine Lainé, Laura Mezquita, Gérôme Jules-Clément, Antoine Hollebecque, Stefan Michiels, Leonardo Panunzi, Ismael Padioleau, Véronique Scott, Loic Verlingue, Guillaume Grisay, Marc Deloger, Luigi Cerbone, Konstantin Gunbin, Andrey A. Yurchenko, Julien Viot, Yoann Pradat
These tables present clinical data, sample data, whole-exome and transcriptome sequencing results, literature references, and external data sources that were used for the analyses presented in the main text.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c2c4dc901030b8bb53e1b607a5cf7f7
https://doi.org/10.1158/2159-8290.22692336
https://doi.org/10.1158/2159-8290.22692336
Autor:
Jenna H. Rannikko, Loic Verlingue, Maria de Miguel, Annika Pasanen, Debbie Robbrecht, Tanja Skytta, Sanna Iivanainen, Shishir Shetty, Yuk Ting Ma, Donna M. Graham, Sukeshi Patel Arora, Panu Jaakkola, Christina Yap, Yujuan Xiang, Jami Mandelin, Matti K. Karvonen, Juho Jalkanen, Sinem Karaman, Jussi P. Koivunen, Anna Minchom, Maija Hollmén, Petri Bono
Clever-1 expression in macrophages contributes to impaired antigen presentation and suppression of anti-tumor immunity. This first-in-human trial was designed to investigate the safety and tolerability of Clever-1 blockade in patients with treatment-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68b8cb2572a9a06baf7e29b63bb2c665
https://doi.org/10.1101/2023.04.17.23288693
https://doi.org/10.1101/2023.04.17.23288693
Autor:
Jean-Charles Soria, Fabrice André, Alexander Eggermont, Gilles Vassal, Eric Angevin, Eric Deutsch, Vincent Ribrag, Catherine Richon, Vladimir Lazar, Jean-Yves Scoazec, Philippe Vielh, Frederic Deschamps, Thierry De Baere, Bastien Job, Nathalie Auger, Ingrid Breuskin, Caroline Even, Yohann Loriot, Sophie Postel-Vinay, Andrea Varga, Anas Gazzah, Rastislav Bahleda, Maud Ngo-Camus, Samy Ammari, Silvia Rosellini, Ecaterina Ileana, Loic Verlingue, Antoine Hollebecque, Ludovic Lacroix, Marie-Cécile Le Deley, Charles Ferté, Stefan Michiels, Christophe Massard
This file provides supplementary methods for genomics, including TGS, CGH array, WES, RNAseq Analysis, IHC -MET.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ba69ab65891380197866f102bd630ba
https://doi.org/10.1158/2159-8290.22532263.v1
https://doi.org/10.1158/2159-8290.22532263.v1